THE IDENTITY
What is RetaBone™?
RetaBone™ is the metabolic-backbone and body-composition research identity of the same Rethiamine formulation. It is not a separate product, not a second formula and not a different strength: it is the lens through which Panacea Bio Chem examines rapid weight loss, lean mass, muscle and nerve function, nutritional status, energy metabolism and bone-health monitoring around one investigational formulation.
The RetaBone name does not mean that the formulation has been demonstrated to increase bone density, prevent fractures or preserve skeletal muscle. These remain separate scientific questions requiring dedicated study.
The formulation itself — definitive product information, platform architecture and development status — is documented at the Rethiamine retatrutide and thiamine formulation site ↗. The thiamine evidence layer lives at the Reta-B1 technical evidence hub ↗. RetaBone owns the body-composition questions: what the retatrutide lean-mass evidence shows, what is known and unknown about bone, and what metabolic resilience actually means.
The proposed formulation — identical across all three identities
- Retatrutide lower layer
- 5 mg
- Thiamine upper layer
- 20 mg thiamine—vitamin B1—with the precise pharmaceutical salt and thiamine-equivalent basis to be declared in the final analytical specification.
- Layer architecture
- dual-layer Peptourbillon™
- Platform
- Lyoprester SS™
- Reconstitution
- 0.5 mL P-EARLs™
- Intended final reconstituted volume
- 0.5 mL
- Developer
- Panacea Bio Chem
- Status
- Proprietary research formulation under development
The same 5 mg + 20 mg formulation appears on Rethiamine.com, Reta-B1.com and RetaBone.com. Three names. Three research perspectives. One proprietary Panacea Bio Chem formulation.
The architecture underneath the identity
Inside the protected lyophilised chamber of Lyoprester SS™, retatrutide forms the frozen lower peptidic layer and thiamine forms a separate supercooled upper layer — co-lyophilised as a dual-layer Peptourbillon™ and kept apart from the 0.5 mL P-EARLs™ reconstitution liquid until activation. This is an engineering objective under validation, described here as exactly that.
- 1
Retatrutide peptidic liquid introduced
The retatrutide-containing peptidic liquid is introduced first into the protected chamber.
- 2
Lower layer frozen
The retatrutide liquid is frozen to create the lower layer of the dual-layer architecture.
- 3
Supercooled thiamine layer positioned
A separately prepared supercooled thiamine-containing liquid is positioned over the frozen retatrutide layer.
- 4
Both layers frozen, spatially separated
The two layers are frozen while preserving their physically distinct layered identity.
- 5
Co-lyophilisation in the protected chamber
Both layers are lyophilised together in the same protected Lyoprester SS chamber — one cycle, one cartridge, no premixed liquid storage.
- 6
0.5 mL P-EARLs activation
The separate 0.5 mL P-EARLs reconstitution chamber is activated immediately before use.
- 7
Rapid unified reconstitution
Both layers form one short-lived injectable preparation immediately before the single shot — an engineering objective under validation.
Why a body-composition identity exists at all
Potent appetite suppression, reduced dietary intake, gastrointestinal intolerance and rapid weight reduction may create nutritional vulnerability in some individuals. When weight falls quickly, what remains — structure, energy, function — becomes a research question in its own right. Panacea Bio Chem is investigating whether integrating thiamine into a once-weekly retatrutide formulation could provide a more coherent pharmaceutical research architecture.
RetaBone is where that question is tracked against the published record: DXA substudies, systematic reviews, nutrition consensus statements and the evidence gaps between them.